Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Jefferies keeps its Buy rating

11/10/2021 | 04:37am EST

Analyst Peter Welford from Jefferies research considers the stock attractive and recommends it with a Buy rating. The target price is lowered from CHF 100 to CHF 95.


ę MarketScreener with dpa-AFX Analyser 2021
All news about NOVARTIS AG
06:41aBioNTech Plans 50% Workforce Boost, $57 Million Investment At German Factory
MT
01/25Merus Regains Worldwide Rights to MCLA-145 After Incyte Opt-Out; Names Chief Commercial..
MT
01/25NOVARTIS AG : Goldman Sachs gives a Buy rating
MD
01/25AlphaValue/Baader Europe Lowers Price Target on Novartis, Upgrades Recommendation to Bu..
MT
01/24NOVARTIS : 2021 Global Managed Access Program Community Update
PU
01/20BAUSCH HEALTH BRIEF : He Will join Bausch + Lomb from Allergan/AbbVie; Prior to that, he w..
MT
01/20NOVARTIS AG : JP Morgan keeps a Sell rating
MD
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
AQ
01/18Novartis CEO Expects Worldwide Normalcy to COVID-19 By 2022-End
MT
01/18GLOBAL MARKETS LIVE : Toyota, Microsoft, Goldman Sachs, Alibaba, Boeing...
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 988 M - -
Net income 2021 24 286 M - -
Net Debt 2021 9 024 M - -
P/E ratio 2021 7,73x
Yield 2021 3,90%
Capitalization 190 B 190 B -
EV / Sales 2021 3,84x
EV / Sales 2022 3,69x
Nbr of Employees 108 000
Free-Float -
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 84,11 $
Average target price 98,49 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-3.81%187 958
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093